Get started

Eli Lilly (Portugal)

Homepage: lilly.com
Parent institution: Eli Lilly (United States)
ROR: 03zd03166
OpenAlex ID: I4405256260
Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity
2025 · Deborah B. Horn, Bruno Linetzky, et al. · JAMA Internal Medicine · 65
Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
2023 · Fernando Magro, Rish K Pai, et al. · Journal of Crohn s and Colitis · 44
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials
2024 · Geert D’Haens, Peter D R Higgins, et al. · Inflammatory Bowel Diseases · 29
PDF
Development and Use of Gene Therapy Orphan Drugs—Ethical Needs for a Broader Cooperation Between the Pharmaceutical Industry and Society
2020 · Sandor Kerpel-Fronius, Varvara Baroutsou, et al. · Frontiers in Medicine · 27
PDF
Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials
2024 · Christoph Wanner, Hristo Iliev, et al. · Advances in Therapy · 25
Linking the Declarations of Helsinki and of Taipei: Critical Challenges of Future-Oriented Research Ethics
2020 · Chieko Kurihara, Varvara Baroutsou, et al. · Frontiers in Pharmacology · 18
PDF
Epidemiological, Social and Economic Burden of Severe Hypoglycaemia in Patients with Diabetes Mellitus in Portugal: A Structured Literature Review
2023 · Ana Rita Soares, Marisa Coelho, et al. · Diabetes Therapy · 11
PDF
The Shared Ethical Responsibility of Medically and Non-medically Qualified Experts in Human Drug Development Teams
2018 · Sandor Kerpel-Fronius, Sander Becker, et al. · Frontiers in Pharmacology · 10
PDF
Burden of Bowel Urgency in Patients With Ulcerative Colitis and Crohn’s Disease: A Real-World Global Study
2024 · Raja Atreya, Isabel Redondo, et al. · Crohn s & Colitis 360 · 9
PDF
Impact of clinical and demographic characteristics on patient preferences for psoriasis treatment features: Results from a discrete-choice experiment in a multicountry study
2021 · Marco Boeri, Daniel Saure, et al. · Journal of Dermatological Treatment · 9
Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint
2025 · Jean-Frederic Colombel, Jianmin Wu, et al. · Journal of Crohn s and Colitis · 3
PDF
Clinical profiles and outcomes in patients with inflammatory bowel disease receiving standard and escalated doses of targeted therapies: findings from a global real-world study
2023 · Axel Dignass, Isabel Redondo, et al. · Current Medical Research and Opinion · 3
PDF
P261 Burden of bowel urgency across specific treatment groups among Ulcerative Colitis patients – real world global study analyses
2022 · R Atreya, I Redondo, et al. · Journal of Crohn s and Colitis · 3
Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe
2023 · Javier P. Gisbert, Petra Streit, et al. · Current Medical Research and Opinion · 2
P554 Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials
2023 · G D'Haens, P D R Higgins, et al. · Journal of Crohn s and Colitis · 2
P64 Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials
2024 · Geert D’Haens, Peter Higgins, et al. · Gut · 1
A184 Early Symptom Control With Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis in the Lucent-1 Induction Trial
2023 · S Danese, A Dignass, et al. · Journal of the Canadian Association of Gastroenterology · 1
PDF
S784 Sustained Symptom Control With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis in the LUCENT-2 Maintenance Trial
2022 · Axel Dignass, Silvio Danese, et al. · The American Journal of Gastroenterology · 1
S755 Early Symptom Control With Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis in the LUCENT-1 Induction Trial
2022 · Silvio Danese, Axel Dignass, et al. · The American Journal of Gastroenterology · 1
P13 Communicating needs and features of IBD experiences (CONFIDE) survey: patient and health care professional perspectives
2022 · Isabel Redondo, David Rubin, et al. · Gut · 1
Corrigendum: Linking the Declarations of Helsinki and of Taipei: Critical Challenges of Future-Oriented Research Ethics
2021 · Chieko Kurihara, Varvara Baroutsou, et al. · Frontiers in Pharmacology · 1
PDF
DOP005 Mirikizumab treatment reduces Crohn’s disease-related surgery and hospitalization rates: analyses from VIVID-1
2026 · B E Sands, F Magro, et al. · Journal of Crohn s and Colitis
S1449 Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With up to 3 Years of Treatment
2024 · Bruce E. Sands, Taku Kobayashi, et al. · The American Journal of Gastroenterology
S1493 The Impact of Mirikizumab Induction, Maintenance, and Long-Term Treatment on Disease Clearance in Patients With Moderately to Severely Active Ulcerative Colitis: Post-Hoc Analysis of LUCENT Trials
2024 · Jean-Frédéric Colombel, Taku Kobayashi, et al. · The American Journal of Gastroenterology
Pos0158-pare Fatigue, Joint and Muscle Pain Are Leading Bothersome Symptoms for Patients With Sle Irrespective of Ethnicity
2024 · J. Cortés-Hernández, E. Haladyj, et al. · Annals of the Rheumatic Diseases
Works count: 33
Citation count: 277
Year
Topic
Type